middle.news
Immutep Surpasses Enrollment Milestone in Pivotal Lung Cancer Trial
8:33am on Wednesday 29th of October, 2025 AEDT
•
Biotechnology
Read Story
Immutep Surpasses Enrollment Milestone in Pivotal Lung Cancer Trial
8:33am on Wednesday 29th of October, 2025 AEDT
Key Points
TACTI-004 Phase III trial surpasses futility analysis enrollment threshold
FDA endorses further development of eftilagimod alfa in head and neck cancer
New Phase II breast cancer trial initiated with neoadjuvant eftilagimod alfa
Four new patents granted, strengthening intellectual property portfolio
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE